The Realities of Novel Gene Therapy Commercialization

Chris Reinhard of Cardium Therapuetics discusses ‘ the realities of novel gene therapy commercialization ‘ in this 2015 presentation . In this presentation, learn about Generx cardiac angiogenic gene therapy, a Phase III product candidate. Download this presentation to understand more about: Discovery Preclinical research Clinical Safety & Technology Medical Utility Addressable Market and much more! Get your copy here! …

Keith Thompson (CGT) announces the creation of Islexa

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …

Bluebirdbio: “Transforming the Lives of Patients with Severe Genetic Disorders”

Cyrus Mozayeni of Bluebirdbio  joined us for Stem Cells & Regenerative Medicine Congress USA 2014 to present about ‘ Transforming the Lives of Patients with Severe Genetic Disorders’ Download his presentation now to understand more about: Potential for one-time transformative treatments for severe genetic and orphan diseases Encouraging clincial safety and efficacy data in beta thalassemia and CCALD with growing clinical pipeline …

Guest Blog: Cord blood – A real lifeline?

Another first for Terrapinn this year was the parallel Cord Blood World Europe Congress running alongside the Stem Cell and Regenerative Medicine Congress at the Business Design Centre in London, far too enticing a proposition not to pop in and take a look. Some ten years ago (or perhaps slightly more) I stood in a GMP suite staring at my …

Video: Highlights from North America’s leading Stem Cell, Cord Blood and Cell Culture events

In September 2013 stem cells, cord blood and cell culture industry executives gathered in Cambridge, MA to network and share insights in these unique but related sectors. Check out the event highlights above. Stem Cells & Regenerative Medicine Congress is where biotechs gather to explore the most promising trends in stem cell, cell and gene therapies. World Cord Blood Congress …

New gene therapy to advance the fight against cancer

Researchers from the Memorial Sloan-Kettering Cancer Center in New York reported this week that the use of gene therapy to manipulate the immune system is emerging as a promising strategy to combat cancer. The treatment involves taking patients T-cells and genetically modifying them to target a protein called CD19, which is present on all acute lymphoblastic leukemia cells. The engineered …

Gene therapy restarts patients’ heart stem cells

In a breakthrough clinical trial on humans, researchers used gene therapy to encourage the heart to repair itself after cardiac damage. Mounting evidence has pointed towards the heart having a regenerative potential but its capacity for regeneration is insufficient to replace the massive loss of cardiomyocytes following ischaemic damage. In this trial, published in Circulation Research, researchers made use of …

Specific Regulatory Challenges of Genetically Modified Cells

With the EMA approving the first gene therapy to treat a rare disease, it is a signal to the healthcare industry as a whole that truly innovative and pioneering therapies are inevitably going to reach the market and transform the health of patients in need. The gene and cell therapy industry's route to market may resemble an un-kept wilderness with …

Achieving reproducible and stable therapeutic gene expression

Are you looking to move your business into developing Gene Therapies?  Would knowing the current situation of lentivectors aid you in deciding how to best achieve this goal? At the recent 2012 World Gene Therapy Congress, part of the 7th annual World Stem Cells and Regenerative Medicine, Dr Michael Antoniou, from the Department of Medical and Molecular Genetics at King’s …